RE: CA 19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Preoperative Therapy
- 7 April 2013
- journal article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 20 (7) , 2108-2110
Abstract
No abstract availableThis publication has 17 references indexed in Scilit:
- CA19-9 in Potentially Resectable Pancreatic Cancer: Perspective to Adjust Surgical and Perioperative TherapyAnnals of Surgical Oncology, 2012
- Adjusting CA19-9 values to predict malignancy in obstructive jaundice: Influence of bilirubin and C-reactive proteinWorld Journal of Gastroenterology, 2012
- Elevation of Carbohydrate Antigen 19.9 in Benign Hepatobiliary Conditions and Its Correlation with Serum Bilirubin ConcentrationDigestive Diseases and Sciences, 2008
- The Use of Adjusted Preoperative CA 19-9 to Predict the Recurrence of Resectable Pancreatic CancerJournal of Surgical Research, 2007
- ASCO 2006 Update of Recommendations for the Use of Tumor Markers in Gastrointestinal CancerJournal of Clinical Oncology, 2006
- The argument for pre-operative chemoradiation for localized, radiographically resectable pancreatic cancerBest Practice & Research Clinical Gastroenterology, 2006
- Elevated tumour marker CA19-9: clinical interpretation and influence of obstructive jaundiceEuropean Journal of Surgical Oncology, 2000
- Clinical use of tumor markers in oncologyCurrent Problems in Cancer, 1991
- Tumor markers: Value and limitations in the management of cancer patientsCancer Treatment Reviews, 1985
- Specific Antigen in Serum of Patients with Colon CarcinomaScience, 1981